Empagliflozin Downregulates AMP‐Activated Protein Kinaseα O‐GlcNAcylation to Ameliorate Hepatic Steatosis
The FASEB Journal · 2025
DOI: 10.1096/fj.202500538rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Yicheng Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: AMP-Activated Protein Kinases, Glucosides, Fatty Liver, Benzhydryl Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: The National Natural Science Foundation of China Grants, Futian Healthcare Research Project, the Graduate Innovation Special Fund of Jiangxi Province.
Abstract (Originalsprache)
The efficacy of the SGLT2 inhibitor empagliflozin (EMPA) in mitigating hepatic steatosis in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease (MASLD) has been previously demonstrated. However, the underlying mechanisms remain unclear. In this study, we investigated the role of EMPA in alleviating hepatic steatosis through the modulation of O‐GlcNAcylation. High‐glucose (HG)–induced alpha mouse liver 12 (AML12) cells, mouse primary hepatocytes (MPHs), and murine MASLD models (high‐fat diet–fed and ob/ob mice) were used to examine the effects of EMPA. Protein O‐GlcNAcylation, lipid accumulation, and AMP‐activated protein kinase α (AMPKα) regulation were evaluated using Western blotting, immunostaining, and siRNA knockdown. Our findings showed that protein O‐GlcNAcylation levels were elevated in both in vitro and in vivo models. EMPA treatment reduced O‐GlcNAcylation and ameliorated lipid accumulation in HG‐induced AML12 cells, MPHs, and MASLD models. Knockdown of O‐GlcNAc transferase (OGT) decreased O‐GlcNAcylation levels and lipid accumulation in HG‐induced AML12 cells. Additionally, OGT knockdown altered both O‐GlcNAcylated and phosphorylated AMPKα levels. In these models, EMPA administration decreased O‐GlcNAcylated AMPKα while increasing phosphorylated AMPKα. This study further identified serine 344, threonine 447, and serine 501 as critical O‐GlcNAcylation sites on AMPKα2. Mutation of these residues to alanine in AMPKα2 attenuated lipid accumulation in AML12 cells, with no additional improvement observed following EMPA treatment. In summary, EMPA effectively improves hepatic steatosis by modulating the O‐GlcNAcylation states of AMPKα. Identification of specific O‐GlcNAcylation sites on AMPKα2 highlights their importance in the therapeutic mechanism of EMPA in improving hepatic steatosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Endocrinology and Metabolic Diseases, The Eighth Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China.
- The Key Laboratory of Diabetes Prevention and Treatment in Guangdong Province, Guangzhou, China.
- Branch of National Clinical Research Center for Metabolic Diseases, Nanchang, China.
- Department of Endocrinology and Metabolism, the Third Affiliated Hospital of SunYat-Sen University, Guangzhou, China.
ORCID-Profile: Yicheng Zhou, Yunfeng Shen
Förderung
- The National Natural Science Foundation of China Grants
- Futian Healthcare Research Project
- the Graduate Innovation Special Fund of Jiangxi Province
- the Sanming Project of Medicine in Shenzhen
- National Natural Science Foundation of China
- Sanming Project of Medicine in Shenzen Municipality
Zitieren
APA
Zhou, Y., Xu, M., Yu, P., Wang, W., Cheng, L., Jiao, X., Zhang, Q., Xiong, H., Yu, P., Chen, Y., Xu, F., & Shen, Y. (2025). Empagliflozin Downregulates AMP‐Activated Protein Kinaseα O‐GlcNAcylation to Ameliorate Hepatic Steatosis. The FASEB Journal. https://doi.org/10.1096/fj.202500538rr
Vancouver
Zhou Y, Xu M, Yu P, Wang W, Cheng L, Jiao X, et al. Empagliflozin Downregulates AMP‐Activated Protein Kinaseα O‐GlcNAcylation to Ameliorate Hepatic Steatosis. The FASEB Journal. 2025. doi:10.1096/fj.202500538rr
BibTeX
@article{Zhou2025,
author = {Zhou, Yicheng and Xu, MinXuan and Yu, Piaojian and Wang, Wei and Cheng, Lidan and Jiao, Xiaojuan and Zhang, Qin and Xiong, Haixia and Yu, Peng and Chen, Yanming and Xu, Fen and Shen, Yunfeng},
title = {Empagliflozin Downregulates AMP‐Activated Protein Kinaseα O‐GlcNAcylation to Ameliorate Hepatic Steatosis},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202500538rr}
}
EUVIMED